Altimmune, Inc. (ALT) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-24

Key Insights

Altimmune raised approximately $211.2 million in net proceeds through a public offering of 64.25 million common shares at $3.00 per share plus accompanying warrants, providing substantial capital for clinical development.
The company plans to use proceeds primarily to advance pemvidutide's global Phase 3 trial in MASH (metabolic dysfunction-associated steatohepatitis), indicating a significant milestone-driven focus on a potentially valuable indication.
Common Stock Warrants have a 5-year expiration or can be triggered early upon successful Phase 3 MASH data readout, creating potential dilution but also tying warrant exercise to clinical success.
The offering structure includes pre-funded warrants with a $0.001 exercise price and no expiration date, suggesting investors are betting on long-term value creation and the company's ability to execute its pipeline.

Want the newest filings?

This analysis covers the filing from 2026-04-24. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-16

Altimmune, Inc. filed an 8-K to announce an amendment to its Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000, which was approved by shareholders at the 2026 Annual Meeting.
The company also reported the results of the shareholder votes at the 2026 Annual Meeting, including the election of directors, ratification of the independent auditor, advisory vote on executive compensation, and approvals for amendments to the company's equity plans.
The increase in authorized shares suggests the company may be planning for future capital raising or corporate actions that would require additional shares, which could be a positive sign for investors.

Filed: 2026-01-28

Altimmune, Inc. has entered into a $75 million registered direct offering with a new institutional investor, which is expected to close on January 29, 2026.
The offering includes the issuance of 12,397,920 shares of common stock and pre-funded warrants to purchase up to 4,647,534 shares of common stock.
The company has also entered into a placement agency agreement with Titan Partners Group LLC, who will act as the sole placement agent for the offering.

Other reports for Altimmune, Inc.

Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.